Dermatology Times

MAY 6, 2024

Elizabeth Kiracofe, MD, provides a look at an upcoming DermView program that will explore systemic treatments for atopic dermatitis in the context of reproductive health, for patients during pregnancy, pre-pregnancy, postpartum, and breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

JANUARY 14, 2024

People with seborrheic dermatitis who don’t use topical steroids are 3.5 Zoryve foam is a once-daily steroid-free topical for use in all skin and hair types that effectively clears and controls seborrheic dermatitis. Food and Drug Administration (FDA) approved topical roflumilast foam (Zoryve, Arcutis) for seborrheic dermatitis.

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. and is the same strength and formulation studied in the ADORING Phase 3 development program and included in the sNDA submission for atopic dermatitis.

Dermatitis 74

Dermatitis Office Management Eczema 74

Dermatology Times

OCTOBER 3, 2023

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

Dermatitis 36

Dermatitis Treatments Safety Dermatology 36

Dermatology Times

JUNE 12, 2024

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dermatitis 36

Dermatitis Treatments Safety 36

The Dermatology Digest

SEPTEMBER 26, 2024

Food and Drug Administration approved for prurigo nodularis (PN), nemolizumab (Nemluvio, Galderma) improved signs and symptoms of atopic dermatitis for more than one year, according to the ARCADIA open-label extension study. The safety profile was consistent with that previously reported, the study showed. Safety is not an issue.

Dermatitis 74

Dermatitis Safety Management Eczema 74

Dermatology Times

JUNE 2, 2024

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Dermatitis 52

Dermatitis Therapy Safety Treatments 52

The Dermatology Digest

JANUARY 20, 2024

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.

Safety 74

Safety Office Dermatitis Clinic 74

Dermatology Times

JUNE 19, 2024

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Treatments 36

Treatments Dermatitis Safety Clinic 36

The Dermatology Digest

FEBRUARY 8, 2024

Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.”

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

Dermatology Times

JULY 8, 2024

Robert Bruce Posnick, MD, examines a case of a 55-year-old female patient with a 50-year history of atopic dermatitis, comorbid asthma, and severe alopecia areata, presenting with recurrent patches throughout her body, predominantly affecting her face, hands, trunk, arms, legs, and eyelids.

Dermatitis 36

Dermatitis Safety Management Treatments 36

Dermatology Times

AUGUST 24, 2023

Experts discuss the results of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

AUGUST 16, 2023

Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

AUGUST 9, 2023

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Safety 36

Safety Dermatitis Treatments 36

Dermatology Times

JULY 10, 2024

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, have a comprehensive discussion on treatment safety considerations for patients with atopic dermatitis who are breastfeeding.

Dermatitis 36

Dermatitis Safety Treatments 36

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

MAY 16, 2024

million, five-year National Institutes of Health (NIH) U01 grant to investigate dupilumab (Dupixent, Sanofi & Regeneron) as a treatment for children with alopecia areata. Current treatment options for alopecia areata harbor negative side effects for long-term use. Dr. Guttman. “If

Eczema 69

Eczema Dermatitis Safety Innovations 69

First Derm

AUGUST 25, 2023

However, it is important to address the misconception that “natural” automatically equates to safety. By addressing the misconception surrounding the safety of natural skin care products, we can better understand the need for careful evaluation and consideration when choosing these products.

Dermatitis 40

Dermatitis Irritation Skincare Sensitive Skin 40

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Vtama cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. Fully 80.7%

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. “It is important to have systemic treatments approved for CHE, both with and without atopic dermatitis. . and Sanofi report. “We

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

APRIL 30, 2024

Eli Lilly has resubmitted its Biologics License Application (BLA) for Lebrikizumab for the treatment of moderate to severe atopic dermatitis (AD), with regulatory action anticipated in the second half of 2024. There were no concerns with lebrikizumab’s clinical data package, safety, or label.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

JANUARY 23, 2024

Nemolizumab improves skin lesions, itch, and sleep disturbance in patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 studies. Galderma’s nemolizumab is a first-in-class interleukin-31 receptor alpha antagonist that is under investigation for atopic dermatitis.

Dermatitis 36

Dermatitis Safety Sustainability Eczema 36

The Dermatology Digest

MARCH 11, 2024

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

JULY 19, 2024

Limiting the use of oral corticosteroid treatment to 90 days or less may limit adverse effects in patients with atopic dermatitis (AD). This is the main takeaway from a new nested case-control study in JAMA Network Open that looked at the long-term use of oral corticosteroids and safety outcomes for AD patients.

Dermatitis 36

Dermatitis Networking Safety Dermatology 36

US Dermatologt Partners

SEPTEMBER 23, 2024

It’s important to develop healthy skin habits to slow the signs of aging around the eyes, and there are also dermatologic treatment options available when you need to hit the reset button.” Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes.

Treatments 41

Treatments Chemical Peels Skincare Routine Sun Protection 41

The Dermatology Digest

JULY 10, 2024

for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

First Derm

DECEMBER 26, 2023

Consult Healthcare Providers When Necessary : Seek professional advice for persistent, severe, or unusual scalp symptoms to ensure accurate diagnosis and effective treatment. Dandruff (Seborrheic Dermatitis) Dandruff, medically known as seborrheic dermatitis , is a common scalp condition marked by excessive shedding of skin cells.

Management 49

Management Dermatitis Eczema Consultation 49

The Dermatology Digest

MARCH 11, 2024

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment. of patients withdrawn from treatment, the study showed.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

The Dermatology Digest

JUNE 14, 2024

Food and Drug Administration (FDA) has cleared InnoCare Pharma’s investigational new drug application (IND) for ICP-332, a tyrosine kinase 2 (TYK2) inhibitor that’s being studied in moderate to severe atopic dermatitis (AD). Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD.

Dermatitis 36

Dermatitis Marketing Safety Innovations 36

The Dermatology Digest

SEPTEMBER 25, 2024

Upadacitinib (Rinvoq, AbbVie) performed well in moderate-to-severe atopic dermatitis (AD) patients with head and neck involvement, according to a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. 307) 67.8 (320) 320) 75.9 (323) 323) 4 to 7.2 severe) 10.5 (152) 152) 47.2 (142) 142) 63.2 (136) 304) 22.3 (319)

Dermatitis 36

Dermatitis Dermatology Eczema Safety 36

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36